DNP002 / Kumho HT, National OncoVenture - LARVOL DELTA

A phase Ia study of DNP002, a monoclonal antibody that binds to tumor-associated CEACAM family proteins, in patients with advanced solid tumors: Interim results from dose escalation study (ESMO Asia 2024) - P1 | "However, DNP002 demonstrated tolerability with limited and manageable toxicity and a partial response observed at 0.03 mg/kg. This study is still ongoing to determine the maximal tolerated dose."

Clinical • IO biomarker • Metastases • P1 data • Esophageal Cancer • Oncology • Solid Tumor • CEACAM1 • CEACAM6

Study of DNP002 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Kumho HT Inc.

Metastases • New P1 trial • Oncology • Solid Tumor